Elanco's Credelio Quattro Breaks New Ground in Multi-Parasite Protection for Dogs
核心洞察
Elanco Animal Health (搜索)'s Credelio Quattro (搜索), a novel oral therapy combining four active ingredients, has received FDA approval for protecting dogs against six types of parasites.
The groundbreaking therapy is the first isoxaline insecticide to include tapeworm coverage, demonstrating 100% efficacy in heartworm and tapeworm prevention in laboratory studies.
The meat-flavored, chewable tablet is approved for dogs and puppies 8 weeks and older weighing at least 3.3 pounds, offering comprehensive parasite protection in a single dose.
Elanco Animal Health (搜索) has launched a groundbreaking parasite protection therapy that marks a significant advancement in veterinary medicine. The FDA-approved Credelio Quattro (搜索), unveiled at the 2025 Veterinary Meeting & Expo in Orlando, Florida, offers comprehensive protection against six parasites, including three intestinal worms with zoonotic potential.
The innovative therapy combines four active ingredients - lotilaner, moxidectin, praziquantel, and pyrantel - in a palatable, meat-flavored chewable tablet. What sets Credelio Quattro (搜索) apart is its distinction as the first and only isoxaline insecticide to incorporate tapeworm coverage, representing a significant leap forward in parasite control.
Clinical Efficacy and Safety Profile
Laboratory studies have demonstrated impressive efficacy rates, with Credelio Quattro (搜索) achieving 100% prevention against both heartworm disease (搜索) and tapeworms. The treatment maintains consistent effectiveness throughout the monthly dosing period, particularly in its action against fleas and ticks.
Dr. Casey Locklear, US medical strategic lead for Elanco Animal Health (搜索) and practicing veterinarian in Texas, emphasized the product's broad spectrum of protection: "Credelio Quattro (搜索) is the broadest isoxaline insecticide, offering coverage against six types of parasites, including tapeworms."
Treatment Specifications and Accessibility
The medication is approved for use in dogs and puppies aged 8 weeks and older, with a minimum weight requirement of 3.3 pounds. The formulation is specifically designed to be meat allergen-free while maintaining palatability.
Healthcare providers and veterinarians can access detailed product information through credelioquattrovet.com. Elanco is featuring the product at the WVC veterinary conference in Las Vegas, where renowned experts Dr. Susan Little and Dr. Brian Herrin will lead educational sessions on the therapy's applications and benefits.
Market Impact and Educational Initiatives
The launch of Credelio Quattro (搜索) represents a significant milestone in veterinary parasitology, offering veterinarians a comprehensive solution for parasite control in a single, convenient formulation. Elanco's commitment to education is evident through their planned conference presentations and daily "quattro hour" information sessions at their booth during the WVC conference.